Literature DB >> 23856596

Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides.

Jamie Heimburg-Molinaro1, Jeffrey W Priest, David Live, Geert-Jan Boons, Xuezheng Song, Richard D Cummings, Jan R Mead.   

Abstract

Glycoproteins expressed by Cryptosporidium parvum are immunogenic in infected individuals but the nature of the epitopes recognised in C. parvum glycoproteins is poorly understood. Since a known immunodominant antigen of Cryptosporidium, the 17kDa glycoprotein, has previously been shown to bind to lectins that recognise the Tn antigen (GalNAcα1-Ser/Thr-R), a large number of glycopeptides with different Tn valency and presentation were prepared. In addition, glycopeptides were synthesised based on a 40kDa cryptosporidial antigen, a polymorphic surface glycoprotein with varying numbers of serine residues, to determine the reactivity with sera from C. parvum-infected humans. These glycopeptides and non-glycosylated peptides were used to generate a glycopeptide microarray to allow screening of sera from C. parvum-infected individuals for the presence of IgM and IgG antibodies. IgG but not IgM in sera from C. parvum-infected individuals bound to multivalent Tn antigen epitopes presented on glycopeptides, suggesting that glycoproteins from C. parvum that contain the Tn antigen induce immune responses upon infection. In addition, molecular differences in glycosylated peptides (e.g. substituting Ser for Thr) as well as the site of glycosylation had a pronounced effect on reactivity. Lastly, pooled sera from individuals infected with either Toxoplasma or Plasmodium were also tested against the modified Cryptosporidium peptides and some sera showed specific binding to glycopeptide epitopes. These studies reveal that specific anti-glycopeptide antibodies that recognise the Tn antigen may be useful diagnostically and in defining the roles of parasite glycoconjugates in infections. Published by Elsevier Ltd.

Entities:  

Keywords:  Cryptosporidium parvum; Glycopeptide microarrays; Plasmodium; Tn antigen; Toxoplasma

Mesh:

Substances:

Year:  2013        PMID: 23856596      PMCID: PMC3937990          DOI: 10.1016/j.ijpara.2013.05.012

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  41 in total

1.  Serum IgG response to Cryptosporidium immunodominant antigen gp15 and polymorphic antigen gp40 in children with cryptosporidiosis in South India.

Authors:  Sitara Swarna Rao Ajjampur; Rajiv Sarkar; Geneve Allison; Kalyan Banda; Anne Kane; Jayaprakash Muliyil; Elena Naumova; Honorine Ward; Gagandeep Kang
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

Review 2.  Use of glycan microarrays to explore specificity of glycan-binding proteins.

Authors:  David F Smith; Xuezheng Song; Richard D Cummings
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 3.  Molecular targets for detection and immunotherapy in Cryptosporidium parvum.

Authors:  Jeanine I Boulter-Bitzer; Hung Lee; Jack T Trevors
Journal:  Biotechnol Adv       Date:  2006-08-30       Impact factor: 14.227

4.  Parallel solid-phase synthesis of mucin-like glycopeptides.

Authors:  Mian Liu; George Barany; David Live
Journal:  Carbohydr Res       Date:  2005-09-26       Impact factor: 2.104

5.  Novel fluorescent glycan microarray strategy reveals ligands for galectins.

Authors:  Xuezheng Song; Baoyun Xia; Sean R Stowell; Yi Lasanajak; David F Smith; Richard D Cummings
Journal:  Chem Biol       Date:  2009-01-30

6.  O-glycosylation in Toxoplasma gondii: identification and analysis of a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.

Authors:  Magdalena M Stwora-Wojczyk; Jessica C Kissinger; Steven L Spitalnik; Boguslaw S Wojczyk
Journal:  Int J Parasitol       Date:  2004-03-09       Impact factor: 3.981

7.  Cation-independent mannose 6-phosphate receptor: a composite of distinct phosphomannosyl binding sites.

Authors:  Richard N Bohnsack; Xuezheng Song; Linda J Olson; Mariko Kudo; Russell R Gotschall; William M Canfield; Richard D Cummings; David F Smith; Nancy M Dahms
Journal:  J Biol Chem       Date:  2009-10-19       Impact factor: 5.157

8.  Determination of immuno-cross-reactivity between Cryptosporidium parvum and Eimeria spp.

Authors:  M J Lorenzo; J A Casal; F Freire; J A Castro; C A Vergara; M E Ares-Mazás
Journal:  Vet Parasitol       Date:  1998-03-31       Impact factor: 2.738

9.  Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies.

Authors:  Oyindasola Oyelaran; Qian Li; David Farnsworth; Jeffrey C Gildersleeve
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

10.  Cryptosporidiosis-an overview.

Authors:  Gordon J Leitch; Qing He
Journal:  J Biomed Res       Date:  2012-02-21
View more
  11 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

3.  CRISPR/Cas9 and glycomics tools for Toxoplasma glycobiology.

Authors:  Elisabet Gas-Pascual; Hiroshi Travis Ichikawa; Mohammed Osman Sheikh; Mariam Isabella Serji; Bowen Deng; Msano Mandalasi; Giulia Bandini; John Samuelson; Lance Wells; Christopher M West
Journal:  J Biol Chem       Date:  2018-11-21       Impact factor: 5.157

4.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

Review 5.  Using glycan microarrays to understand immunity.

Authors:  Connie M Arthur; Richard D Cummings; Sean R Stowell
Journal:  Curr Opin Chem Biol       Date:  2014-01-29       Impact factor: 8.822

6.  Glycan Array Technology.

Authors:  Juana Elizabeth Reyes Martinez; Baptiste Thomas; Sabine Lahja Flitsch
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

7.  Competition between serum IgG, IgM, and IgA anti-glycan antibodies.

Authors:  Saddam M Muthana; Li Xia; Christopher T Campbell; Yalong Zhang; Jeffrey C Gildersleeve
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

8.  Cryptosporidium parvum vaccine candidates are incompletely modified with O-linked-N-acetylgalactosamine or contain N-terminal N-myristate and S-palmitate.

Authors:  John R Haserick; Joshua A Klein; Catherine E Costello; John Samuelson
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

9.  Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.

Authors:  Julie L Lucas; Erin A Tacheny; Allison Ferris; Michelle Galusha; Apurva K Srivastava; Aniruddha Ganguly; P Mickey Williams; Michael C Sachs; Magdalena Thurin; James V Tricoli; Winnie Ricker; Jeffrey C Gildersleeve
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

10.  Development of smart anti-glycan reagents using immunized lampreys.

Authors:  Tanya R McKitrick; Christoffer K Goth; Charles S Rosenberg; Hirotomo Nakahara; Jamie Heimburg-Molinaro; Alyssa M McQuillan; Rosalia Falco; Nicholas J Rivers; Brantley R Herrin; Max D Cooper; Richard D Cummings
Journal:  Commun Biol       Date:  2020-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.